EVP R&D, Chief Medical Officer
Mon, Dec 9, 2024
Dec 9
exercised or converted securities in ALKS
12,044 shares @ $24.59
Increased holdings by +14.30%
Net across this filing: -20.30% (-12,154 shares)
Option Exercise
Sale tied to a same-time option exercise